Sialic Acid Compositions for Competitive Blocking of Coronavirus Attachment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for safe and effective compositions to inhibit or treat infections caused by SARS-CoV-2, which can lead to COVID-19, particularly for individuals at higher risk or those already infected.
Innovation Solution
The use of sialic acid compositions, such as N-acetylneuraminic acid (NANA), administered in effective concentrations, to inhibit or treat SARS-CoV-2 infections by increasing the natural content of sialic acid in the nasal mucosa, potentially through nasal sprays, gels, or oral formulations, thereby blocking viral attachment to epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sialic acid compositions are administered to inhibit viral attachment, then viral infection is reduced, but the concentration and dosage requirements may increase treatment complexity
Solution Approach 1:
The patent specifies precise concentration ranges (0.1 to 100 mg/ml) and pH ranges (2.0 to 4.0) for sialic acid compositions to optimize viral attachment inhibition while minimizing side effects. These parameter optimizations resolve the contradiction by establishing reliable therapeutic concentrations that reduce treatment complexity through standardized dosing protocols.
Solution Approach 2:
The patent uses sialic acid as a molecular copy or analog of natural cellular receptors that viruses target. By administering exogenous sialic acid compositions, the treatment creates a competitive environment where the virus binds to the administered sialic acid instead of cellular receptors, effectively copying the receptor function to block infection.
2Reliability
If effective concentrations of sialic acid are used to block viral attachment, then prophylaxis and treatment efficacy improve, but the quantity of substance required increases
Solution Approach 1:
The patent establishes specific concentration ranges (0.1 to 100 mg/ml) and pH ranges (2.0 to 4.0) that optimize the therapeutic effect of sialic acid. By defining these precise parameters, the patent reduces the quantity of substance needed while maintaining high prophylaxis and treatment efficacy, as the optimized concentrations achieve maximum viral attachment inhibition without requiring excessive amounts.
3Adaptability or versatility
If multiple administration routes and formulations are provided, then adaptability to different patient needs improves, but device and formulation complexity increases
Solution Approach 1:
The patent provides sialic acid compositions that can be administered through multiple routes (oral, intranasal, topical, parenteral) using a single active ingredient. This multi-functional approach increases adaptability to different patient needs and infection scenarios while avoiding the complexity of developing entirely separate treatments for each administration route, as the core sialic acid composition remains consistent across different delivery methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Sialic acid compositions effectively inhibit viral attachment and infection by competing with cellular receptors, reducing the risk of infection and potentially alleviating symptoms associated with SARS-CoV-2.
Implementation Method 1
Sialic acid compositions effectively inhibit viral attachment and infection by competing with cellular receptors
Data Source
AI summary
The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).